These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22361686)

  • 21. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
    Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
    Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
    Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
    Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
    Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
    Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
    Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
    Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of novel chalcone derivatives as antitubulin agents.
    Zhang H; Liu JJ; Sun J; Yang XH; Zhao TT; Lu X; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 May; 20(10):3212-8. PubMed ID: 22503741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
    Kadioglu O; Saeed MEM; Greten HJ; Mayr K; Schrama D; Roos WP; Efferth T
    J Am Acad Dermatol; 2021 Apr; 84(4):1086-1089. PubMed ID: 32707252
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
    Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
    J Med Chem; 2006 Jan; 49(1):407-16. PubMed ID: 16392826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAF
    Wang CR; Wang ZF; Shi L; Wang ZC; Zhu HL
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2382-2390. PubMed ID: 29934244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF
    Abou-Zied HA; Beshr EAM; Gomaa HAM; Mostafa YA; Youssif BGM; Hayallah AM; Abdel-Aziz M
    Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200464. PubMed ID: 36526595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
    Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
    J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
    Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
    Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
    J Med Chem; 2008 Jun; 51(11):3261-74. PubMed ID: 18473434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells.
    Ramisetti SR; Pandey MK; Lee SY; Karelia D; Narayan S; Amin S; Sharma AK
    Eur J Med Chem; 2018 Jan; 143():1919-1930. PubMed ID: 29133035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.